183 related articles for article (PubMed ID: 15896974)
1. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress influences CC-chemokine levels in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Nephron Physiol; 2004; 96(4):p105-12. PubMed ID: 15122056
[TBL] [Abstract][Full Text] [Related]
3. Inflammation but not oxidative stress is associated with beta-chemokine levels and prevalence of cardiovascular disease in uraemic patients.
Pawlak K; Pawlak D; Myśliwiec M
Cytokine; 2006 Sep; 35(5-6):258-62. PubMed ID: 17070067
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis intensified oxidative stress, MIP-1beta and RANTES plasma levels in uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2004 Dec; 28(6):197-204. PubMed ID: 15566948
[TBL] [Abstract][Full Text] [Related]
5. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Atherosclerosis; 2007 Jan; 190(1):199-204. PubMed ID: 16510149
[TBL] [Abstract][Full Text] [Related]
6. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease.
Pawlak K; Pawlak D; Mysliwiec M
Clin Biochem; 2007 Jan; 40(1-2):81-5. PubMed ID: 17046733
[TBL] [Abstract][Full Text] [Related]
7. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
[TBL] [Abstract][Full Text] [Related]
8. Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Haemost; 2004 Sep; 92(3):646-53. PubMed ID: 15351863
[TBL] [Abstract][Full Text] [Related]
9. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
10. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
12. Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study.
Young L; Katrib A; Cuello C; Vollmer-Conna U; Bertouch JV; Roberts-Thomson PJ; Ahern MJ; Smith MD; Youssef PP
Arthritis Rheum; 2001 Feb; 44(2):343-50. PubMed ID: 11229465
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
14. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
[TBL] [Abstract][Full Text] [Related]
15. Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2004; 24(6):635-40. PubMed ID: 15627719
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
17. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
19. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
20. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
